Design, synthesis and biological evaluation of chalcone based compounds in Alzheimer's disease

Abstract

Alzheimer�s disease (AD), a complex neurodegenerative brain disorder, a most common cause of dementia among elderly people. To date, the AD is being managed by maintaining the levels of acetylcholine by inhibiting acetylcholinesterase (AChE). Following this approach, a new series of Chalcones were designed, synthesized and biologically evaluated against acetylcholinesterase (AChE) with additional free radical scavenging activity. The in vitro studies showed that the majority of synthesized derivatives inhibited acetylcholinesterase (AChE) with IC50 values in the micro molar range. Some of the derivatives strongly inhibited AChE. Besides AChE inhibitory activity, these compounds also exhibited greater ability to scavenge free radicals. Thus, chalcones might be the promising lead compound as potential antiAlzheimer�s agents.